Inflammatory Bowel DiseasesCONNECT-IBDNCT02539368
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease
An observational study of Inflammatory Bowel Diseases and Ulcerative Colitis, run by Pfizer at 140 sites in 13 countries.
Trial summary
This is a post-marketing observational study of patients with Inflammatory Bowel Disease (specifically, Crohn's disease or Ulcerative Colitis) who have been prescribed CT-P13 (infliximab) or Remicade (infliximab) for treatment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn's Disease
- What is being tested?
- CT-P13 and Remicade
- How many people
- 2,565 participants
- Where
- 140 sitesin 13 countries
- Study dates
- 22 Apr 2015to 31 Oct 2018
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The target study population will include patients with CD or UC, who are being treated, or initiating treatment, with CT-P13 or Remicade at the time of study enrolment. This would include the following treatment subgroups: * Biologic-naïve patients initiating CT-P13 (or Remicade); * Patients currently being treated with CT-P13 (or Remicade); * Patients who are considered stable by the Investigator under Remicade therapy for CD or UC, who switch to CT-P13; * Patients switching to CT-P13 or Remicade from an alternative biologic therapy (e.g. adalimumab) due to non-responsiveness to or intolerance; * Patients re-initiating CT-P13 or Remicade after having successfully completed and exited a previous course of infliximab therapy in the past. * Patients with fistulating disease or stomas and those receiving combination therapy will be included.
Who may be able to join
- At least 12 years of age at the time of initial confirmed diagnosis of CD or UC and at least 18 years of age at the time of enrolment to the study.
- Patients who are prescribed CT-P13 or Remicade for the treatment of CD or UC prescribed according to the corresponding summary of product characteristics (SmPC) as determined by the Investigator. Patients with stomas or surgery/pouch will be included.
Who cannot join
- Any reported contraindications for CT-P13 or Remicade, according to the SmPC.
- Known hypersensitivity (including severe, acute infusion reactions) to infliximab, its excipients or other murine proteins, at the time of enrolment.
- Prior history of failure to respond to Remicade or CT-P13.
Trial locations and contacts
140 sites in 13 countries.
140 sites in 13 countries
France30 sites
CHU Amiens
Amiens, 80054
CHU Angers
Angers, 49933
CHRU de Besancon
Besançon, 25030
Centre Hospitalier Universitaire
Caen, 14033
Clinique de Bercy
Charenton, 94220
CHU Clermontferrand
Clermont-Ferrand, 63003
Hopital Beaujon
Clichy, 92110
Hôpital Louis Mourier
Colombes, 92700
CHU de Grenoble
Grenoble, 38043
CHRU
Lille, 59000
Hopital Edouard Herriot Pav H
Lyon, 69003
Hopital Europeen
Marseille, 13003
Hopital Nord
Marseille, 13015
CHU
Montpellier, 34295
CHU Nimes
Nîmes, 30029/Cedex 9
Hôpital Saint-Antoine, AP-HP, Universite Pierre-et-Marie-Curie
Paris, 75012
Hopital Cochin
Paris, 75014
Institut Montsouris
Paris, 75014
Hôpital Européen Georges Pompidou
Paris, 75015
Hopital St Louis
Paris, 75475
CHU Lyon Sud
Pierre-Bénite, 69495
Hopital Metz Tessy
Pringy, 74374
Hopital Robert Debre
Reims, 51000
Chu Ch.Nicolle
Rouen, 76031
Service: CHU saint-etienne
Saint Priez En Jarez, 42270
Centre Hospitalier Universitaire
Strasbourg, 67098
CHU Rangueil
Toulouse, 31059
Hopital Purpan
Toulouse, 31059
CHU Nancy
Vandœuvre-lès-Nancy, 54511
Groupe hospitalier mutualiste les portes du Sud
Vénissieux, 69694
Germany25 sites
Gemeinschaftspraxis im MEDICUM
Altenholz, 24161
Gastroenterologische Praxis Dr. med. B. Adami
Alzey, 55232
Studienzentrum Aschaffenburg
Aschaffenburg, 63739
Gastroenterologie Am Bayerischen Platz
Berlin, 10825
Kreiskliniken Altotting-Burghausen
Burghausen, 84489
Interdisciplinaeres Crohn-Colitis Centrum Rhein-Main
Frankfurt am Main, 60594
Gemeinschaftspraxis Dr. R Denger und Dr. T. Pfitzner
Friedrichsthal, 66299
PraxisZentrum fuer Gastroenterologie
Grevenbroich, 41515
Hamburgisches Forschungsinstitut fur chronisch entzuendliche
Hamburg, 20148
Gastroenterologische Gemeinschaftspraxis Herne
Herne, 44623
Internisten am Markt Dres. Schwerdtfeger & Lehmann
Köthen, 06366
Internistische Gemeinschaftspraxis fuer Verdauungs- und Stoffwechselerkrankungen
Leipzig, 04229
Onco Studies an der Onkologie Dreiländereck
Loerrach, 79539
St. Marienkrankenhaus
Ludwigshafen am Rhein, Gartenstadt, 67076
Universitaetsmedizin Mannheim
Mannheim, 68135
Magen-Darm Praxis Prof. Dr. Krammer & Kollegen
Mannheim, 68165
Gastroenterologische Gemeinschaftspraxis Minden
Minden, 32423
Praxis Prof.Dr. med. Herbert Kellner
Muenchen-Nymphenburg, 80639
Medizinisches Versorgungszentrum Portal 10
Münster, 48155
Gastroenterologische Gemeinschaftspraxis am Germania-Campus
Münster, 48159
Praxiszentrum Alte Maelzerei
Regensburg, 93053
Magen-Darm-Zentrum Remscheid
Remscheid, 42859
Zentrum für Gastroenterologie Saarbrücken MVZ GmbH
Saarbrücken, 66111
Ambulanzzentrum-Schweinfurt
Schweinfurt, 97421
Gastroenterologische Schwerpunktpraxis Stuttgart
Stuttgart, 70178
Italy23 sites
Fondazione Poliambulanza - Istituto Ospedaliero
Brescia, 25124
Azienda Ospedaliera per l'Emergenza Cannizzaro
Catania, 95100
Azienda Ospedaliero Universitaria - Policlinico "Vittorio Emanuele"
Catania, 95123
Università degli Studi "G. d'Annunzio" Chieti - Pescara
Chieti, 66100
ASL 11 Empoli - Ospedale San Giuseppe
Empoli, FI, 50053
ASUR Area Vasta n. 4 - Ospedale A. Murri
Fermo, 63900
Azienda Ospedaliero Universitaria Careggi
Florence, FI, 50134
Azienda Ospedaliera Universitaria Careggi
Florence, 50134
Università degli Studi di Genova
Genova, 16132
A.O.U. Policlinico "G.Martino"
Messina, 98125
Azienda Ospedaliera - Universitaria di Modena Policlinico
Modena, 41124
Ospedale "Sacro Cuore - Don Calabria"
Negrar, Verona, 27024
Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
Palermo, 90127
Az.Osp. Ospedali Riuniti 'Villa Sofia-Cervello
Palermo, 90146
Azienda Ospedaliero-Universitaria di Parma
Parma, PR, 43126
AOUP - Ospedale di Cisanello
Pisa, 56124
Azienda Ospedaliera Universitaria di PISA
Pisa, 56124
Ospedale Generale Provinciale di Macerata
Province of Macerata, 62100
Ospedale Sandro Pertini
Roma, 00157
Ospedale San Camillo
Rome, 00152
Presidio Ospedaliero "M. Raimondi"
San Cataldo (Caltanisetta), Caltanisetta, 93100
I.R.C.C.S. Policlinico San Donato
San Donato Milanese, Milano, 20097
A.O.U. "S. Maria della Misericordia di Udine"
Udine, 33100
Spain23 sites
Hospital de Alcorcon
Alcorcón, Madrid, 28922
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, 08916
Hospital Arquitecto Marcide
Ferrol, A Coruna, 15405
Hospital Universitario de Fuenlabrada
Fuenlabrada, Madrid, 28942
Hospital Universitari de Girona Dr. Josep Trueta
Girona, Barcelona, 17007
Hospital Universitario de Gran Canaria DR NEGRIN
Las Palmas de Gran Canari, Canary Islands, 35010
Hospital Universitario La Princesa
Madrid, 28006
Hospital Universitario Gregorio Marañon
Madrid, 28007
Hospital Ramon y Cajal
Madrid, 28034
Hospital Clinico San Carlos
Madrid, 28040
Hospital Fundación Jiménez Díaz
Madrid, 28040
Hospital Universitario La Paz
Madrid, 28046
Hospital Son Espases
Palma. Mallorca, Balearic Islands, 07120
Complejo Hospitalario de Navarra
Pamplona, Navarre, 31008
Hospital Alvaro Cunqueiro
Pontevedra, 36312
Hospital de Sabadell
Sabadell, Barcelona, 08208
Hospital Universitario Infanta Sofia
San Sebastian de Los Reye, Madrid, 28702
Hospital Clinico Universitario de Santiago
Santiago de Compostela, A Coruna, 15706
Hospital de Galdakao
Usansolo, Bizkaia, 48960
Hospital Clínico de Valencia
Valencia, 46010
Consorci Hospital General Universitari de Valencia
Valencia, 46014
Hospital Universitari i Politecnic La Fe
Valencia, 46026
Hospital Clinico Universitario de Valladolid
Valladolid, 47005
United Kingdom10 sites
Heart of England NHS Foundation Trust
Birmingham, B9 5SS
The Royal Bournemouth Hospital
Bournemouth, BH7 7DW
University Hospital Coventry
Coventry, WEST Midlands, CV2 2DX
Dorset County Hospital
Dorchester, Dorset, DT1 2JY
Royal Gwent Hospital
Exeter, Devon, EX2 5DW
Gloucestershire Hospitals - NHS Foundation Trust
Gloucester, Gloucestershire, GL1 3NN
Queen Alexandra Hospital
Hampshire, PO6 3LY
Cwm Taf University Health Board
Llantrisant, Wales, CF72 8XR
Salisbury NHS Foundation Trust
Salisbury, Wiltshire, SP2 8BJ
Southampton General Hospital
Southampton, SO16 6YD
Greece7 sites
Hippokration General Hospital of Athens
Athens, Attica, 11527
Evangelismos Hospital
Athens, 10676
Venizeleio Hospital of Heraklion
Heraklion, Crete, 71409
University Hospital of Ioannina
Ioannina, 455 00
University Hospital of Larissa
Larissa, 41110
University Hospital of Patras
Rio, Patra, Achaia, 265 04
General Hospital of Thessaloniki Ippokrateio
Thessaloniki, 54642
Czechia5 sites
Fakultni Nemocnice Hradec Kralove
Hradec Králové, 500 05
Hradecká Poliklinika III, HEPATO-GASTROENTEROLOGIE HK, s.r.o
Hradec Králové, 500 12
Centrum péce o zažívací trakt, Vítkovická nemocnice
Ostrava - Vitkovice, 703 84
IKEM (Institut Klinické a Experimentální Medicíny)
Prague, 140 21
Nemocnice Na Bulovce
Praha 8 Liben, 180 81
Portugal4 sites
Hospital Prof. Doutor Fernando Fonseca E.P.E
Amadora, Lisbon District, 2720-276
Centro Hospitalar Barreiro Montijo, E.P.E
Barreiro, 2830-003
Centro Hospitalar Lisboa Norte, E.P.E.- Hospital Santa Maria
Lisbon, 1649-035
Centro Hospitalar entre Douro e Vouga E.P.E.
Santa Maria Da Feira, Porto District, 4520-211
Finland3 sites
Keski-Suomen keskussairaala
Jyväskylä, FI-40620
Oulu University Hospital
Oulu, 90220
Turku University Hospital
Turku, 20521
Hungary3 sites
Semmelweis University
Budapest, H-1088
MH Egeszsegugyi Kozpont - Honvedkorhaz
Budapest, H-1134
Szte szent-gyorgyi albert klinikai kozpont
Szeged, H-6725
Netherlands3 sites
Ziekenhuis Gelderse Vallei
Ede, 6716 RP
Catharina Ziekenhuis
Eindhoven, 5623
Rijnstate
Gelderland, 6815 AD
Belgium2 sites
UZ Antwerpen
Edegem, 2650
UZ Leuven Campus Gasthuisberg
Leuven, Vlaams Brabant, 3000
Slovakia2 sites
FNsP F. D. Roosevelta Banska Bystrica
Banská Bystrica, 974 01
V. interna klinika LFUK a UNB, Ambulancia pre nespecificke zapalove ochorenia
Bratislava, 826 06
About this study
Official title: POST-MARKETING OBSERVATIONAL COHORT STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) TREATED WITH CT-P13 IN USUAL CLINICAL PRACTICE (CONNECT-IBD)
This is a post-marketing observational study of patients with Inflammatory Bowel Disease (specifically, Crohn's disease or Ulcerative Colitis) who have been prescribed CT-P13 (infliximab) or Remicade (infliximab) for treatment. CT-P13 (brand names Inflectra and Remsima) is a biosimilar medicine to Remicade, meaning it is a biologic medicine that contains the same active substance as Remicade (infliximab). The key study objectives are as follows:
- To characterize the population and drug utilization patterns of patients treated with CT-P13 for Crohn's Disease (CD) or Ulcerative Colitis (UC) in the context of standard of care Remicade
- To explore the long-term safety profile of CT-P13 in the treatment of patients with CD or UC in the context of standard of care Remicade
- To assess the effectiveness of CT-P13 in the treatment of patients with CD or UC in the context of standard of care Remicade
Read the detailed description
The study will be conducted in accordance with legal and regulatory requirements with scientific purpose, value and rigor following generally accepted research practices described in Guidelines for Good Pharmacoepidemiology Practices (GPP), Good Epidemiological Practice (GEP), Good Practices for Outcomes Research, International Ethical Guidelines for Epidemiological Research, European Medicines Agency (EMA) European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology, and FDA Guidance for Industry. Data sources will be validated and will consist of the hospital medical records and monitoring will be organized on a regular basis. Data for the study will be entered into a web based electronic data capture (EDC) system at enrolment and then approximately every 3 months (at a minimum) thereafter up to 2 years. Adverse events will be encoded according to MedDRA 17.1 or later. The sample size will be approximately 2500 patients recruited over a 30 month period and followed up to 2 years. No inferential analyses are planned. Statistical analysis will be descriptive in nature.
- Being tested
- CT-P13, Remicade
- Keywords
- CT-P13, Inflectra, Remicade, Infliximab, Observational, Follow-up, Safety, Effectiveness
- Medical subject headings
- Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CT-P13Drug
Also called Inflectra, Remsima
biosimilar infliximab
RemicadeDrug
infliximab
| Study group | Role | What they receive |
|---|---|---|
| CT-P13 | biosimilar infliximab Receives: Drug: CT-P13 | |
| Remicade | infliximab Receives: Drug: Remicade |
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease Characteristics of Participants: Disease Duration
Disease duration was defined as the number of months from initial diagnosis of inflammatory bowel disease (CD or UC) to the date of informed consent, which was recorded at the time of enrollment into the study (baseline).
Measured: Baseline (Day 1)
Number of Participants Who Switched Treatment
Here, number of participants with either UC or CD, who switched from remicade to CT-P13; switched from CT-P13 to remicade and multiple switchers were reported.
Measured: From baseline to follow-up period (up to a maximum duration of 2 years)
Reasons for Switching Treatment by Participants
Measured: From baseline to follow-up period (up to a maximum duration of 2 years)
Total Dose of Infusion Received
Total dose of infusion received by the participants was calculated.
Measured: From baseline to follow-up period (up to a maximum duration of 2 years)
Number of Participants by Frequency of Infusion Received
Number of participants by infusion frequency (weeks) were reported at baseline and categorized as follows: once a week; once every 2 weeks; once every 3 weeks; once every 4 weeks; once every 5 weeks; once every 6 weeks; once every 7 weeks; once every 8 weeks and others. Here, 'Others' category included all the frequencies apart from the mentioned categories.
Measured: Baseline (Day 1)
Number of Participants Who Had Change in Infusion Dose
Participants who had change in the dose of infusion (either dose reduction or increase in dose) were included and reported.
Measured: From baseline to follow-up period (up to a maximum duration of 2 years)
Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change
Participants who had change in infusion dose due to various reasons such as principal investigator's decision, participant's decisions, loss of response, lack of compliance, hypersensitivity, occurrence of adverse event (including adverse event special interest [AESI]/ serious adverse event [SAE]), positive for antibodies and other were reported. Here, 'Others' category included all reasons apart from the mentioned categories. A participant could have different reasons of dose change across visits, hence could be counted in more than one category.
Measured: From baseline to follow-up period (up to a maximum duration of 2 years)
Number of Participants Who Took Concomitant Medications Related to the Treatment of Crohn's Disease (CD) or Ulcerative Colitis (UC)
Measured: From baseline to follow-up period (up to a maximum duration of 2 years)
Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs)
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Treatment-emergent were events between first dose of infusion up to month 24, that were absent before treatment or that worsened relative to pretreatment state. Hypersensitivity was the pre-defined TEAE of special Interest for this study. AEs included both serious and non-serious adverse events.
Measured: From baseline to follow-up period (up to a maximum duration of 2 years)
Secondary outcomes (14)
Number of Participants Remaining in Clinical Remission or Relapse
Clinical remission in participants was defined by a total Mayo score of 2 points or lower, with no individual sub score exceeding 1 point. Mayo score is an instrument designed to measure disease activity. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and physician's global assessment, each sub score graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease. The relapse of clinical remission was defined as the time from the date of first attaining CR to the date of relapse or death from any cause, whichever occurred first.
Measured: Months 6, 12, 18 and 24
Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission
HBI is a simple index of CD activity. HBI measures 5 parameters; the general well-being (ranging from 0=very well to 4=terrible), abdominal pain ranging from 0 (none) to 3 (severe), number of liquid stools per day (no maximum score), presence of an abdominal mass on physical exam ranging from 0 (none) to 3 (definite and tender), and whether there are any complications ranging from 0=no complications, 1=Arthralgia; 2=Uveitis; 3=Erythema nodosum; 4=Aphthous ulcer; 5=Pyoderma gangrenosum; 6=Anal fissure; 7=New fistula and 8=abscess). The total HBI score is the sum of all the 5 individual parameters, the minimum score is 0 and there was no pre-specified maximum score as it depends on the number of liquids stools. Higher HBI scores=greater disease activity. The level of disease activity was interpreted as clinical remission (CR) (score less than [<] 5), mild disease (MD) (score equal to [=] 5 to 7), moderate disease (Mod D) (score=8 to 16) and severe disease (SD) (score more than [>] 16).
Measured: Baseline, Months 6, 12, 18 and 24
Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity
HBI is a simple index of CD activity. HBI measures 5 clinical parameters; the general well-being ranging from 0 (very well) to 4 (terrible), abdominal pain ranging from 0 (none) to 3 (severe), number of liquid stools per day (no maximum score), presence of an abdominal mass on physical exam ranging from 0 (none) to 3 (definite and tender), and whether there are any complications ranging from 0=no complications, 1=Arthralgia; 2=Uveitis; 3=Erythema nodosum; 4=Aphthous ulcer; 5=Pyoderma gangrenosum; 6=Anal fissure; 7=New fistula and 8=abscess). The total HBI score is the sum of all the 5 individual parameters, the minimum score is 0 and there was no pre-specified maximum score as it depends on the number of liquids stools. Higher HBI scores=greater disease activity. The level of disease activity was interpreted as clinical remission (CR) (HBI score < 5), mild disease (MD) (HBI score = 5 to 7), moderate disease (Mod D) (HBI score = 8 to 16) and severe disease (SD) (HBI score >16).
Measured: Baseline, Months 6, 12, 18 and 24
Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission
Mayo Score is an instrument to measure disease activity of UC. Score ranges from 0 to 12 points. It consists of 4 sub scores, each graded from 0 to 3. Higher scores = more severe disease. A Partial Mayo Score (PMS) (Mayo score without endoscopy) is comprised of 3 parameters: stool frequency ranging from 0 (normal number of stools) to 3 (having >=5 stools more than normal), the presence of rectal bleeding (ranging from 0=no blood seen to 3=blood alone passes), and physician's global assessment (ranging from 0=normal to 3=severe disease). The total partial Mayo score was the sum of all the parameters, score ranging from 0 (normal or inactive disease) to 9 (severe disease). Higher scores indicated more severe disease. The score was calculated if data were available for at least 1 of 3 Mayo sub scores. The level of disease activity was interpreted as clinical remission (CR) (PMS <2), mild disease (MD) (PMS=2 to 4), moderate disease (Mod D) (PMS=5 to 6) and severe disease (SD) (PMS >6).
Measured: Baseline, Months 6, 12, 18 and 24
Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity
Mayo Score is an instrument to measure disease activity of UC. Score ranges from 0 to 12 points. It consists of 4 sub scores, each graded from 0 to 3. Higher scores= more severe disease. A Partial Mayo Score (PMS) (Mayo score without endoscopy) is comprised of 3 parameters: stool frequency ranging from 0 (normal number of stools) to 3 (having >=5 stools more than normal), the presence of rectal bleeding ranging from 0 (no blood seen) to 3 (blood alone passes), and physician's global assessment ranging from 0 (normal) to 3 (severe disease). The total partial Mayo score was the sum of all the parameters, score ranging from 0 (normal or inactive disease) to 9 (severe disease). Higher scores indicated more severe disease. The score was calculated if data were available for at least 1 of 3 Mayo sub scores. The level of disease activity was interpreted as clinical remission (CR) (PMS <2), mild disease (MD) (PMS=2 to 4), moderate disease (Mod D) (PMS=5 to 6) and severe disease (SD) (PMS >6).
Measured: Baseline, Months 6, 12, 18 and 24
Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis
The Montreal classification index for CD was used to classify the extent of the disease activity. It consisted of three parameters: age at diagnosis, location and behavior of the disease activity. There were four different age groups categorized: 16 years or younger, 17-40 years, over 40 years and missing.
Measured: At Baseline
Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location
The Montreal classification index for CD was used to classify the extent of the disease activity. It consisted of three parameters: age at diagnosis, location and behavior of the disease activity. There are four different disease locations presented: Location 1 (L1) is terminal ileum, Location 2 (L2) is colon, Location 3 (L3) is ileocolon and Location 4 (L4) is upper gastrointestinal (GI). The first three categories (L1-L3) was combined with L4 where disease sites coexisted.
Measured: Baseline, Months 6, 12, 18 and 24
Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity
The Montreal classification index for CD was used to classify the extent of the disease activity. It consists of two parameters: location and behavior of the disease activity. There were 4 different categories for the behavior of the disease activity: Behaviour 1 (B1) was nonstricturing (NS), nonpenetrating (NP); Behaviour 2 (B2) was structuring; Behaviour 3 (B3) was penetrating and p as perianal disease (p). The first 3 categories (B1 to B3) could be added with p to indicate coexisting perianal disease. Perianal disease (p) was defined as the presence of perianal abscesses or fistulae.
Measured: Baseline, Months 6, 12, 18 and 24
Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent
The Montreal classification index for Ulcerative Colitis (UC) was used to classify the extent and severity of the disease activity. There were three subgroups of UC defined by extent: Extent 1 (E1) =Ulcerative proctitis, Extent 2 (E2) =Left-sided UC and Extent 3 (E3) =Extensive UC.
Measured: Baseline, Months 6, 12, 18 and 24
Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity
The Montreal classification index for UC was used to classify the extent and severity of the disease activity. UC can be classified broadly into four disease activity/severity categories: Severity 0 (S0) = asymptomatic clinical remission; Severity 1 (S1) = Mild UC (passage of four or fewer stools/day [with or without blood], absence of any systemic illness, and normal inflammatory markers); Severity 2 (S2) = Moderate UC (passage of more than four stools per day but with minimal signs of systemic toxicity) and Severity 3 (S3) = Severe UC (passage of at least six bloody stools daily).
Measured: Baseline, Months 6, 12, 18 and 24
Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index
The fistula drainage assessment index was used to assess the improvement or remission of the disease activity of Crohn's Disease, based on 6 categories: remission (remission was defined as closure of all fistulae that were draining at baseline for at least two consecutive visits); improvement (improvement defined as a decrease from baseline in the number of open draining fistulae of 50% for at least two consecutive visits); worsened; unchanged; not accessible and missing disease activity.
Measured: Baseline, Months 6, 12, 18 and 24
Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24
C-reactive protein (CRP) was a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultra-sensitive assay. A decrease in the level of CRP indicated reduction in inflammation and therefore improvement.
Measured: Baseline, Months 6, 12, 18 and 24
Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24
Here, the laboratory tests related to the treatment or assessment of Crohn's Disease or Ulcerative Colitis was fecal calprotectin.
Measured: Baseline, Months 6, 12, 18, and 24
Number of Participants With Imaging Test Results
Number of participants who had Imaging test results related to the treatment or assessment of Crohn's Disease or Ulcerative Colitis were reported.
Measured: From baseline up to follow-up period (a maximum of 2 years)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Sep 2015 (estimated)
- Study start22 Apr 2015
- Primary completion31 Oct 2018
- Study completion31 Oct 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Inflammatory Bowel DiseasesStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,565 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Hospira, now a wholly owned subsidiary of Pfizer
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02539368
- Sponsor's protocol ID
- ZOB INF 1402
- Other IDs
- C1231001
- Acronym
- CONNECT-IBD
- Status last verified
- Jan 2020
- First submitted
- 22 Jul 2015
- Last updated
- 13 Feb 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Publications
Bokemeyer B, Hlavaty T, Allez M, Selema P, Moosavi S, Cadatal MJ, Fowler H, Mueller M, Liau KF, Gisbert JP. Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD). Expert Opin Biol Ther. 2023 Jul-Dec;23(8):791-800. doi: 10.1080/14712598.2023.2200883. Epub 2023 Apr 16.
PubMed 37038897
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- POST-MARKETING OBSERVATIONAL COHORT STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) TREATED WITH CT-P13 IN USUAL CLINICAL PRACTICE (CONNECT-IBD)
- ClinicalTrials.gov ID
- NCT02539368
- Acronym / sponsor ID
- CONNECT-IBD / ZOB INF 1402
- Keywords
- CT-P13, Inflectra, Remicade, Infliximab, Observational, Follow-up, Safety, Effectiveness
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,565 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Collaborators
- Hospira, now a wholly owned subsidiary of Pfizer
- Study start
- 22 Apr 2015 (actual)
- Primary completion
- 31 Oct 2018 (actual)
- Study completion
- 31 Oct 2018 (actual)
- First posted
- 3 Sep 2015 (estimated)
- Results
- Posted 13 Feb 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a post-marketing observational study of patients with Inflammatory Bowel Disease (specifically, Crohn's disease or Ulcerative Colitis) who have been prescribed CT-P13 (infliximab) or Remicade (infliximab) for treatment. CT-P13 (brand names Inflectra and Remsima) is a biosimilar medicine to Remicade, meaning it is a biologic medicine that contains the same active substance as Remicade (infliximab). The key study objectives are as follows:
- To characterize the population and drug utilization patterns of patients treated with CT-P13 for Crohn's Disease (CD) or Ulcerative Colitis (UC) in the context of standard of care Remicade
- To explore the long-term safety profile of CT-P13 in the treatment of patients with CD or UC in the context of standard of care Remicade
- To assess the effectiveness of CT-P13 in the treatment of patients with CD or UC in the context of standard of care Remicade
Detailed description
The study will be conducted in accordance with legal and regulatory requirements with scientific purpose, value and rigor following generally accepted research practices described in Guidelines for Good Pharmacoepidemiology Practices (GPP), Good Epidemiological Practice (GEP), Good Practices for Outcomes Research, International Ethical Guidelines for Epidemiological Research, European Medicines Agency (EMA) European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology, and FDA Guidance for Industry. Data sources will be validated and will consist of the hospital medical records and monitoring will be organized on a regular basis. Data for the study will be entered into a web based electronic data capture (EDC) system at enrolment and then approximately every 3 months (at a minimum) thereafter up to 2 years. Adverse events will be encoded according to MedDRA 17.1 or later. The sample size will be approximately 2500 patients recruited over a 30 month period and followed up to 2 years. No inferential analyses are planned. Statistical analysis will be descriptive in nature.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CT-P13 | – | Drug: CT-P13biosimilar infliximab |
| Remicade | – | Drug: Remicadeinfliximab |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The target study population will include patients with CD or UC, who are being treated, or initiating treatment, with CT-P13 or Remicade at the time of study enrolment. This would include the following treatment subgroups: * Biologic-naïve patients initiating CT-P13 (or Remicade); * Patients currently being treated with CT-P13 (or Remicade); * Patients who are considered stable by the Investigator under Remicade therapy for CD or UC, who switch to CT-P13; * Patients switching to CT-P13 or Remicade from an alternative biologic therapy (e.g. adalimumab) due to non-responsiveness to or intolerance; * Patients re-initiating CT-P13 or Remicade after having successfully completed and exited a previous course of infliximab therapy in the past. * Patients with fistulating disease or stomas and those receiving combination therapy will be included.
Key inclusion criteria (2 listed)
- At least 12 years of age at the time of initial confirmed diagnosis of CD or UC and at least 18 years of age at the time of enrolment to the study.
- Patients who are prescribed CT-P13 or Remicade for the treatment of CD or UC prescribed according to the corresponding summary of product characteristics (SmPC) as determined by the Investigator. Patients with stomas or surgery/pouch will be included.
Key exclusion criteria (3 listed)
- Any reported contraindications for CT-P13 or Remicade, according to the SmPC.
- Known hypersensitivity (including severe, acute infusion reactions) to infliximab, its excipients or other murine proteins, at the time of enrolment.
- Prior history of failure to respond to Remicade or CT-P13.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CT-P13Also: Inflectra, Remsimabiosimilar infliximab | Drug | CT-P13 |
| Remicadeinfliximab | Drug | Remicade |
Primary outcome
Disease Characteristics of Participants: Disease Duration
Time frame: Baseline (Day 1)
Disease duration was defined as the number of months from initial diagnosis of inflammatory bowel disease (CD or UC) to the date of informed consent, which was recorded at the time of enrollment into the study (baseline).
Number of Participants Who Switched Treatment
Time frame: From baseline to follow-up period (up to a maximum duration of 2 years)
Here, number of participants with either UC or CD, who switched from remicade to CT-P13; switched from CT-P13 to remicade and multiple switchers were reported.
Reasons for Switching Treatment by Participants
Time frame: From baseline to follow-up period (up to a maximum duration of 2 years)
Total Dose of Infusion Received
Time frame: From baseline to follow-up period (up to a maximum duration of 2 years)
Total dose of infusion received by the participants was calculated.
Number of Participants by Frequency of Infusion Received
Time frame: Baseline (Day 1)
Number of participants by infusion frequency (weeks) were reported at baseline and categorized as follows: once a week; once every 2 weeks; once every 3 weeks; once every 4 weeks; once every 5 weeks; once every 6 weeks; once every 7 weeks; once every 8 weeks and others. Here, 'Others' category included all the frequencies apart from the mentioned categories.
Number of Participants Who Had Change in Infusion Dose
Time frame: From baseline to follow-up period (up to a maximum duration of 2 years)
Participants who had change in the dose of infusion (either dose reduction or increase in dose) were included and reported.
Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change
Time frame: From baseline to follow-up period (up to a maximum duration of 2 years)
Participants who had change in infusion dose due to various reasons such as principal investigator's decision, participant's decisions, loss of response, lack of compliance, hypersensitivity, occurrence of adverse event (including adverse event special interest [AESI]/ serious adverse event [SAE]), positive for antibodies and other were reported. Here, 'Others' category included all reasons apart from the mentioned categories. A participant could have different reasons of dose change across visits, hence could be counted in more than one category.
Number of Participants Who Took Concomitant Medications Related to the Treatment of Crohn's Disease (CD) or Ulcerative Colitis (UC)
Time frame: From baseline to follow-up period (up to a maximum duration of 2 years)
Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs)
Time frame: From baseline to follow-up period (up to a maximum duration of 2 years)
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Treatment-emergent were events between first dose of infusion up to month 24, that were absent before treatment or that worsened relative to pretreatment state. Hypersensitivity was the pre-defined TEAE of special Interest for this study. AEs included both serious and non-serious adverse events.
14 secondary outcomes
Number of Participants Remaining in Clinical Remission or Relapse
Time frame: Months 6, 12, 18 and 24
Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission
Time frame: Baseline, Months 6, 12, 18 and 24
Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity
Time frame: Baseline, Months 6, 12, 18 and 24
Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission
Time frame: Baseline, Months 6, 12, 18 and 24
Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity
Time frame: Baseline, Months 6, 12, 18 and 24
Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis
Time frame: At Baseline
Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location
Time frame: Baseline, Months 6, 12, 18 and 24
Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity
Time frame: Baseline, Months 6, 12, 18 and 24
Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent
Time frame: Baseline, Months 6, 12, 18 and 24
Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity
Time frame: Baseline, Months 6, 12, 18 and 24
Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index
Time frame: Baseline, Months 6, 12, 18 and 24
Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24
Time frame: Baseline, Months 6, 12, 18 and 24
Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24
Time frame: Baseline, Months 6, 12, 18, and 24
Number of Participants With Imaging Test Results
Time frame: From baseline up to follow-up period (a maximum of 2 years)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 37038897Bokemeyer B, Hlavaty T, Allez M, Selema P, Moosavi S, Cadatal MJ, Fowler H, Mueller M, Liau KF, Gisbert JP. Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD). Expert Opin Biol Ther. 2023 Jul-Dec;23(8):791-800. doi: 10.1080/14712598.2023.2200883. Epub 2023 Apr 16.
- Individual participant dataSharing planned: No. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Inflammatory Bowel Diseases
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Multidimensional Dynamic Early Warning System for Neonatal Necrotizing Enterocolitis: A Multicenter Clinical Study
NEC - Necrotizing Enterocolitis
Recruiting
Effect of Mediterranean Diet in Inflammatory Bowel Disease
Inflammatory Bowel Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
140 sites in 13 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Inflammatory Bowel Diseases and Ulcerative Colitis, run by Pfizer at 140 sites in 13 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 140 sites in France, Germany, Italy, Spain, United Kingdom and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 13 Feb 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Disease Characteristics of Participants: Disease Duration (time frame: Baseline (Day 1)). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02539368, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2020.